Zydus Lifesciences Limited

Total Valuation

Zydus Lifesciences Limited carries a market capitalization of 1.16T, placing it among publicly traded companies globally. Its enterprise value stands at 995.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

Zydus Lifesciences Limited trades at a trailing price-to-earnings ratio of 21.77.

Enterprise Valuation

On an enterprise value basis, Zydus Lifesciences Limited trades at an EV/EBITDA multiple of 16.94 and an EV/FCF ratio of 594.41. The EV/Sales ratio of 4.33 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.94 provides insight into valuation relative to core operating earnings.

Financial Position

Zydus Lifesciences Limited maintains a current ratio of 4.16, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.98, indicating elevated leverage, while an interest coverage ratio of 26.92 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Zydus Lifesciences Limited has paid 14.10B in income taxes, reflecting an effective tax rate of 23.31.

Stock Price Statistics

Zydus Lifesciences Limited's stock has gained approximately 16.88114% over the past 52 weeks. The 50-day moving average sits at 1,047.50, while the 200-day moving average is 958.47.

Income Statement

Over the trailing twelve months, Zydus Lifesciences Limited generated 229.94B in revenue and converted that into 45.72B in net income, yielding earnings per share of 46.83. EBITDA reached 58.79B, while operating income came in at 58.79B.

Margins

Zydus Lifesciences Limited operates with a gross margin of 71.55, reflecting its pricing power and cost economics. The operating margin of 25.57 and net profit margin of 19.88 provide insight into operational efficiency.

Stock Splits

Zydus Lifesciences Limited's most recent stock split took place on October 6, 2015 with a 1:5 split ratio.

Scores

Zydus Lifesciences Limited posts an Altman Z-Score of 18.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.